Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil

被引:0
|
作者
Koper, Agnieszka [1 ,2 ]
Wilenski, Slawomir [3 ,4 ]
Sledzinska, Paulina [5 ]
Bebyn, Marek [5 ]
Koper, Krzysztof [2 ,6 ]
机构
[1] Nicolaus Copernicus Univ Torun, Dept Oncol, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
[2] Franciszek Lukaszczyk Oncol Ctr, Dept Oncol, PL-85796 Bydgoszcz, Poland
[3] Nicolaus Copernicus Univ Torun, Dept Pharmaceut Technol, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
[4] Hosp Pharm, F Lukaszczyk Oncol Ctr, Cent Cytostat Drug Dept, PL-85796 Bydgoszcz, Poland
[5] 10th Mil Res Hosp & Polyclin, PL-85681 Bydgoszcz, Poland
[6] Nicolaus Copernicus Univ Torun, Dept Clin Oncol & Nursing, Dept Oncol Surg, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
关键词
Chemotherapy; Colorectal cancer; Prognostic factors; Trifluridine/Tipiracil; TAS-102; MONOTHERAPY; PLUS BEVACIZUMAB; DOUBLE-BLIND; OPEN-LABEL; HYPERTENSION; SURVIVAL; THERAPY; REGORAFENIB; CETUXIMAB; TRIAL;
D O I
10.1007/s00432-023-04909-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The systemic treatment options for metastatic colorectal cancer (mCRC) are unsatisfactory, and the disease recurs despite the use of numerous medications and their combinations. Trifluridine/Tipiracil is a relatively new drug used in refractory mCRC. Little is known about its real-world effectiveness and prognostic and predictive factors. Therefore, this study aimed to develop a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil. Methods We retrospectively evaluated the data from 163 patients who had received Trifluridine/Tipiracil as a third or fourth line of treatment for refractory mCRC. Results After starting Trifluridine/ Tipiracil, 21.5% of patients survived one year, and the median overall survival after Trifluridine/Tipiracil initiation was 251 days (SD: 17.855; 95%CI: 216-286). Median progression-free survival after Trifluridine/Tipiracil initiation was 56 days (SD: 4.826; 95%CI 47- 65). Moreover, the median overall survival from diagnosis was 1333 days (SD: 82.84; 95%CI: 1170-1495). In forward stepwise multivariate Cox regression analysis, initial radical treatment (HR = 0.552, 95% CI 0.372-0.819, p < 0.003), the number of cycles of first-line chemotherapy (HR = 0.978, 95% CI 0.961-0.995, p < 0.011), the number of cycles of second-line chemotherapy (HR = 0.955, 95% CI 0.931-0.98, p < 0.011), BRAF mutation (HR = 3.016, 95% CI = 1.207-7.537, p = 0.018), and hypertension (HR = 0.64, 95% CI = 0.44-0.931, p = 0.02) were all associated with survival after Trifluridine/Tipiracil initiation. Our model and model-based nomogram displayed an AUC of 0.623 for one-year survival estimation in the testing cohort. The C-index for the prediction nomogram was 0.632. Conclusion We have developed a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil based on five variables. Moreover, we reported a nomogram which could be used by oncologists in clinic visits on a daily basis.y
引用
收藏
页码:10867 / 10877
页数:11
相关论文
共 50 条
  • [41] Trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer treatment
    Michel, Patryk S.
    Jankowski, Marek
    Sigorski, Dawid
    Kubiatowski, Tomasz
    ONCOLOGY IN CLINICAL PRACTICE, 2024, 20 (06):
  • [42] A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer
    Zou, Jiayun
    Wang, Yuanyuan
    Xu, Jiayu
    Li, Jinna
    Wang, Tianzhuo
    Zhang, Ying
    Bai, Yibo
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)
  • [43] Factors associated with effectiveness of trifluridine/tipiracil versus regorafenib in patients with pretreated metastatic colorectal cancer (mCRC)
    Grell, Peter
    Borilova, Simona
    Schwanzerova, Renata
    Kukolikova, Sabina
    Dvorak, Josef
    Vocka, Michal
    John, Stanislav
    Buchler, Tomas
    Selingerova, Iveta
    Petruzelka, Lubos B.
    Vyzula, Rostislav
    Kiss, Igor
    Obermannova, Radka
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [44] Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia
    Price, Timothy
    Burge, Matthew
    Chantrill, Lorraine
    Gibbs, Peter
    Pavlakis, Nick
    Shapiro, Jeremy
    Sjoquist, Katrin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 3 - 12
  • [45] Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ROS study.
    Garcia-Alfonso, Pilar
    Munoz Martin, Andres J.
    Jimenez-Castro, Jeronimo
    Jimenez-Fonseca, Paula
    Pericay, Carles
    Longo, Federico
    Reyna, Carmen
    Argiles, Guillem
    Gonzalez Astorga, Beatriz
    Jose Gomez-Reina, Maria
    Ruiz Casado, Ana
    Rodriguez-Salas, Nuria
    Lopez-Lopez, Rafael
    Carmona Bayonas, Alberto
    Conde-Herrero, Veronica
    Aranda, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Safety and efficacy of trifluridine/tipiracil monotherapy in metastatic colorectal cancer
    Aparicio Rubio, C.
    Monteagudo Santolaya, E.
    Cornejo Uixeda, S.
    Prieto Castello, M.
    Antonino de la Camara, G.
    Quintana Vergara, B.
    Sanchez Alcaraz, A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 373 - 374
  • [47] Trifluridine/tipiracil in metastatic colorectal cancer: a guide to its use
    Lyseng-Williamson K.A.
    Burness C.B.
    Duggan S.T.
    Drugs & Therapy Perspectives, 2017, 33 (3) : 110 - 118
  • [48] The REWRITE Study-REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer
    Marques, D.
    Costa, A. L.
    Mansinho, A.
    Quintela, A.
    Pratas, E.
    Brito-da-Silva, J.
    Cruz, J.
    Felix, J.
    Rodrigues, J.
    Mota, M.
    Teixeira, A. R.
    Damaso, S.
    Pinheiro, S.
    Andreozzi, V.
    Costa, L.
    Barros, A. G.
    CLINICAL ONCOLOGY, 2023, 35 (10) : 665 - 672
  • [49] Cost-Utility Analysis of Trifluridine/ Tipiracil in treating Metastatic Colorectal Cancer in Previously Treated Patients in Jordan
    Al Rabayah, Abeer
    Sawalha, Razan
    Jaddoua, Saad
    MEDICAL DECISION MAKING, 2024, 44 (02) : NP90 - NP91
  • [50] Trifluridine/tipiracil (FTD/TPI) in extensively pre-treated metastatic colorectal cancer (mCRC) patients: Evaluation of prognostic subgroups of the TALLISUR study
    Karthaus, Meinolf
    Weiss, Lena
    Riera-Knorrenschild, Jorge
    Kretzschmar, Albrecht
    Welslau, Manfred
    Vehling-Kaiser, Ursula
    Pelz, Henning
    Ettrich, Thomas Jens
    Held, Swantje
    Kehrmann, Linde
    Hess, Juergen
    Reislaender, Timo
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)